These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 23199479)

  • 1. Development of small-molecule P-gp inhibitors of the N-benzyl 1,4-dihydropyridine type: novel aspects in SAR and bioanalytical evaluation of multidrug resistance (MDR) reversal properties.
    Baumert C; Günthel M; Krawczyk S; Hemmer M; Wersig T; Langner A; Molnár J; Lage H; Hilgeroth A
    Bioorg Med Chem; 2013 Jan; 21(1):166-77. PubMed ID: 23199479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytotoxic and multidrug resistance reversal activities of novel 1,4-dihydropyridines against human cancer cells.
    Shekari F; Sadeghpour H; Javidnia K; Saso L; Nazari F; Firuzi O; Miri R
    Eur J Pharmacol; 2015 Jan; 746():233-44. PubMed ID: 25445037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-activity relationships of novel N-acyloxy-1,4-dihydropyridines as P-glycoprotein inhibitors.
    Voigt B; Coburger C; Monár J; Hilgeroth A
    Bioorg Med Chem; 2007 Aug; 15(15):5110-3. PubMed ID: 17533131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of pyridine-2-ones as novel class of multidrug resistance (MDR) modulators: first structure-activity relationships.
    Krawczyk S; Otto M; Otto A; Coburger C; Krug M; Seifert M; Tell V; Molnár J; Hilgeroth A
    Bioorg Med Chem; 2011 Nov; 19(21):6309-15. PubMed ID: 21964185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular docking studies and in vitro screening of new dihydropyridine derivatives as human MRP1 inhibitors.
    Sirisha K; Shekhar MC; Umasankar K; Mahendar P; Sadanandam A; Achaiah G; Reddy VM
    Bioorg Med Chem; 2011 May; 19(10):3249-54. PubMed ID: 21530277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistent reversal of P-glycoprotein-mediated daunorubicin resistance by tetrandrine in multidrug-resistant human T lymphoblastoid leukemia MOLT-4 cells.
    Liu ZL; Hirano T; Tanaka S; Onda K; Oka K
    J Pharm Pharmacol; 2003 Nov; 55(11):1531-7. PubMed ID: 14713364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
    Chen LM; Liang YJ; Ruan JW; Ding Y; Wang XW; Shi Z; Gu LQ; Yang XP; Fu LW
    J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological evaluation of bishydroxymethyl-substituted cage dimeric 1,4-dihydropyridines as a novel class of p-glycoprotein modulating agents in cancer cells.
    Richter M; Molnár J; Hilgeroth A
    J Med Chem; 2006 May; 49(9):2838-40. PubMed ID: 16640345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 4,5-Di-substituted benzyl-imidazol-2-substituted amines as the structure template for the design and synthesis of reversal agents against P-gp-mediated multidrug resistance breast cancer cells.
    Zhang N; Zhang Z; Wong IL; Wan S; Chow LM; Jiang T
    Eur J Med Chem; 2014 Aug; 83():74-83. PubMed ID: 24952376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multidrug resistance reversal properties and cytotoxic evaluation of representatives of a novel class of HIV-1 protease inhibitors.
    Coburger C; Lage H; Molnár J; Langner A; Hilgeroth A
    J Pharm Pharmacol; 2010 Dec; 62(12):1704-10. PubMed ID: 21054396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Substituted tetrahydroisoquinoline compound B3 inhibited P-glycoprotein-mediated multidrug resistance in-vitro and in-vivo.
    Fang W; Li Y; Cai Y; Kang K; Yan F; Liu G; Huang W
    J Pharm Pharmacol; 2007 Dec; 59(12):1649-55. PubMed ID: 18053326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.
    Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K
    Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of drug resistance in P-glycoprotein-expressing T-cell acute lymphoblastic CEM leukemia cells by copper N-(2-hydroxy acetophenone) glycinate and oxalyl bis (N-phenyl) hydroxamic acid.
    Majumder S; Dutta P; Mukherjee P; Datta ER; Efferth T; Bhattacharya S; Choudhuri SK
    Cancer Lett; 2006 Nov; 244(1):16-23. PubMed ID: 16410038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumour-specific cytotoxicity and MDR-reversal activity of dihydropyridines.
    Engi H; Sakagami H; Kawase M; Parecha A; Manvar D; Kothari H; Adlakha P; Shah A; Motohashi N; Ocsovszki I; Molnár J
    In Vivo; 2006; 20(5):637-43. PubMed ID: 17091771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of P-glycoprotein-mediated multidrug resistance by a synthetic α-aminoxy peptidomimetic.
    Ma B; Chai S; Li N; To KK; Kan WL; Yang D; Lin G
    Int J Pharm; 2012 Mar; 424(1-2):33-9. PubMed ID: 22226881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of multidrug resistance in cancer cells by novel asymmetrical 1,4-dihydropyridines.
    Firuzi O; Javidnia K; Mansourabadi E; Saso L; Mehdipour AR; Miri R
    Arch Pharm Res; 2013 Nov; 36(11):1392-402. PubMed ID: 23674129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolongation of pentoxifylline aliphatic side chain positively affects the reversal of P-glycoprotein-mediated multidrug resistance in L1210/VCR line cells.
    Docolomanský P; Fialová I; Barancík M; Rybár A; Breier A
    Gen Physiol Biophys; 2005 Dec; 24(4):461-6. PubMed ID: 16474189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dihydropyridines and atypical MDR: a novel perspective of designing general reversal agents for both typical and atypical MDR.
    Miri R; Mehdipour A
    Bioorg Med Chem; 2008 Sep; 16(18):8329-34. PubMed ID: 18701304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.
    Koo JS; Choi WC; Rhee YH; Lee HJ; Lee EO; Ahn KS; Bae HS; Ahn KS; Kang JM; Choi SU; Kim MO; Lu J; Kim SH
    Life Sci; 2008 Nov; 83(21-22):700-8. PubMed ID: 18845169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel indirubin derivative PHII-7 potentiates adriamycin cytotoxicity via inhibiting P-glycoprotein expression in human breast cancer MCF-7/ADR cells.
    Shi R; Li W; Zhang X; Zhang Y; Peng H; Xie Y; Fan D; Liu R; Liu X; Xiong D
    Eur J Pharmacol; 2011 Nov; 669(1-3):38-44. PubMed ID: 21871878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.